Hern-Tze Tina Tan1,2, Kazunari Sugita1,3,4, Cezmi A Akdis5,6. 1. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Platz, Switzerland. 2. Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia. 3. Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. 4. Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Tottori University Faculty of Medicine, Yonago, Japan. 5. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Platz, Switzerland. akdisac@siaf.uzh.ch. 6. Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. akdisac@siaf.uzh.ch.
Abstract
PURPOSE OF REVIEW: The development of biological therapies has rapidly progressed during the last few years, and major advances were reported for the treatment of allergic diseases, such as atopic dermatitis, allergic rhinitis, urticaria, food allergy, and asthma. Here, we review biologicals targeting the type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, natural killer T cells, mast cells, basophils, and epithelial cells, such as IL-4, IL-5, IL-13, IL-31, tumor necrosis factor alpha (TNF-α), and thymic stromal lymphopoietin (TSLP). RECENT FINDINGS: The biologicals that have been currently approved for asthma are omalizumab targeting IgE and reslizumab and mepolizumab targeting interleukin (IL)-5. Many other monoclonal antibodies are currently in various phases of clinical development. The new biological therapies for allergic diseases will eventually be tailored to the endotypes of these diseases and the identification of novel biomarkers. Further development of novel biologicals for the treatment of allergic diseases and asthma will be possible upon improved understanding of mechanisms of allergic diseases. Accordingly, further refinement of endotypes of allergen-specific and non-specific type 2 immune response and related inflammatory mediators is needed for optimal treatment of allergic diseases.
PURPOSE OF REVIEW: The development of biological therapies has rapidly progressed during the last few years, and major advances were reported for the treatment of allergic diseases, such as atopic dermatitis, allergic rhinitis, urticaria, food allergy, and asthma. Here, we review biologicals targeting the type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, natural killer T cells, mast cells, basophils, and epithelial cells, such as IL-4, IL-5, IL-13, IL-31, tumor necrosis factor alpha (TNF-α), and thymic stromal lymphopoietin (TSLP). RECENT FINDINGS: The biologicals that have been currently approved for asthma are omalizumab targeting IgE and reslizumab and mepolizumab targeting interleukin (IL)-5. Many other monoclonal antibodies are currently in various phases of clinical development. The new biological therapies for allergic diseases will eventually be tailored to the endotypes of these diseases and the identification of novel biomarkers. Further development of novel biologicals for the treatment of allergic diseases and asthma will be possible upon improved understanding of mechanisms of allergic diseases. Accordingly, further refinement of endotypes of allergen-specific and non-specific type 2 immune response and related inflammatory mediators is needed for optimal treatment of allergic diseases.
Authors: Christopher E Brightling; Fiona A Symon; Surinder S Birring; Peter Bradding; Ian D Pavord; Andrew J Wardlaw Journal: J Allergy Clin Immunol Date: 2002-12 Impact factor: 10.793
Authors: William W Busse; Stephen Holgate; Edward Kerwin; Yun Chon; Jingyuan Feng; Joseph Lin; Shao-Lee Lin Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: Anne Kirsten; Henrik Watz; Frauke Pedersen; Olaf Holz; Rachel Smith; Gerard Bruin; Stephan Koehne-Voss; Helgo Magnussen; David A Waltz Journal: Eur Respir J Date: 2013-01 Impact factor: 16.671
Authors: Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes Journal: N Engl J Med Date: 2014-05-20 Impact factor: 91.245
Authors: Michael Noonan; Phillip Korenblat; Sofia Mosesova; Heleen Scheerens; Joseph R Arron; Yanan Zheng; Wendy S Putnam; Merdad V Parsey; Sean P Bohen; John G Matthews Journal: J Allergy Clin Immunol Date: 2013-05-29 Impact factor: 10.793
Authors: R Sharon Chinthrajah; Joseph D Hernandez; Scott D Boyd; Stephen J Galli; Kari C Nadeau Journal: J Allergy Clin Immunol Date: 2016-04 Impact factor: 10.793
Authors: Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245
Authors: J Morgan Knight; Pijus Mandal; Pietro Morlacchi; Garbo Mak; Evan Li; Matthew Madison; Cameron Landers; Brandon Saxton; Ed Felix; Brian Gilbert; Joel Sederstrom; Atul Varadhachary; Melissa M Singh; Dev Chatterjee; David B Corry; John S McMurray Journal: J Biol Chem Date: 2018-05-08 Impact factor: 5.157
Authors: Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek Journal: Int Forum Allergy Rhinol Date: 2018-02 Impact factor: 3.858
Authors: Samuel Philip Nobs; Sara Natali; Lea Pohlmeier; Katarzyna Okreglicka; Christoph Schneider; Michael Kurrer; Federica Sallusto; Manfred Kopf Journal: J Exp Med Date: 2017-08-10 Impact factor: 14.307